US Food and Drug Administration approval of esketamine and brexanolone

Lancet Psychiatry. 2019 Dec;6(12):975-977. doi: 10.1016/S2215-0366(19)30292-5. Epub 2019 Nov 1.

Authors

Ioana A Cristea¹, Florian Naudet²

Affiliations

¹ Department of Brain and Behavioral Sciences University of Pavia, 27100 Pavia, Italy; Department of Clinical Psychology and Psychotherapy, Babes-Bolyai University, 400015 Cluj-Napoca, Romania; Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, CA, USA. Electronic address: ioana.cristea@unipv.it.
² University Rennes, CHU Rennes, Inserm, CIC 1414, Rennes, France.

PMID: 31680013
DOI: 10.1016/S2215-0366(19)30292-5

No abstract available

MeSH terms

Antidepressive Agents / adverse effects
Antidepressive Agents / therapeutic use*
Depression, Postpartum / drug therapy*
Depressive Disorder, Treatment-Resistant / drug therapy*
Drug Combinations
Female
Humans
Ketamine / adverse effects
Ketamine / therapeutic use*
Pregnanolone / adverse effects
Pregnanolone / therapeutic use*
United States
United States Food and Drug Administration / standards*
beta-Cyclodextrins / adverse effects
beta-Cyclodextrins / therapeutic use*

Substances

Antidepressive Agents
Drug Combinations
beta-Cyclodextrins
brexanolone
Esketamine
Ketamine
Pregnanolone